T-type calcium channel as a new therapeutic target for tremor

Cerebellum

Volumn 10, Issue 3, 2011, Pages 563-569

  Miwa, Hideto ^a   Kondo, Tomoyoshi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Essential tremor; Harmaline; Parkinson's disease; T type calcium channel; Tremor; Zonisamide

Indexed keywords

2 [2 [N [(3 BENZIMIDAZOL 2 YL)PROPYL] N METHYLAMINO]ETHYL] 6 FLUORO 1,2,3,4 TETRAHYDRO 1 ISOPROPYL 2 NAPHTYLCYCLOPROPANECARBOXYLATE DIHYDROCHLORIDE; 3 ETHYL 2 (PIPERIDIN 1 YL) 4 [N 4 (4 TOLUENESULFONAMIDO)BENZYLACETAMIDO] 3,4 DIHYDROQUINAZOLINE; AMILORIDE; ANTIPARKINSON AGENT; AROTINOLOL; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CAV3.1 CHANNEL; ETHOSUXIMIDE; KYS 05064; LOMERIZINE; MIBEFRADIL; NNC 55 0396; PLACEBO; PRIMIDONE; PROPRANOLOL; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

ARTICLE; BASAL GANGLION; CALCIUM CURRENT; CEREBELLUM DISEASE; DEPOLARIZATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; ENVIRONMENTAL DISEASE; EPILEPSY; EPILEPTOGENESIS; HUMAN; NERVE CELL; NERVE EXCITABILITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; TREMOR;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; HUMANS; MODELS, BIOLOGICAL; TREMOR;

EID: 80455164782     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-011-0277-y     Document Type: Article

References (61)

1. Tröster AI, Fields JA, Pahwa R, Wilkinson SB, Strait-Tröster KA, Lyons K, et al. Neuropsychological and quality of life outcome after thalamic stimulation for essential tremor. Neurology. 1999;53:1774-80. (Pubitemid 29530354)
2. Lorenz D, Schwieger D, Moises H, Deuschl G. Quality of life and personality in essential tremor patients. Mov Disord. 2006;21:1114-8. (Pubitemid 44336594)
3. Lorenz D, Poremba C, Papengut F, Schreiber S, Deuschl G. The psychosocial burden of essential tremor in an outpatient- and a community-based cohort. Eur J Neurol. 2011 Jan 18 doi:10.1111/ j.1468-1331.2010.03295.x.
4. Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713-20. (Pubitemid 34557011)
5. Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg. 1996;84:203-14. (Pubitemid 26039470)
6. Krack P, Benazzouz A, Pollak P, Limousin P, Piallat B, Hoffmann D, et al. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord. 1998;13:907-14. (Pubitemid 28517667)
7. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339:1105-11. (Pubitemid 28465758)
8. Deuschl G, Elble R. Essential tremor - neurodegenerative or nondegenerative disease towards a working definition of ET. Mov Disord. 2009;24:2033-41.
9. Quinn NP, Schneider SA, Schwingenschuh P, Bhatia KP. Tremor - some controversial aspects. Mov Disord. 2011;26:18-23.
10. Llinás R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary neurones and their pharmacological modulation: an in vitro study. J Physiol. 1986;376:163-82. (Pubitemid 16058128)
11. Gutnick MJ, Yarom Y. Low threshold calcium spikes, intrinsic neuronal oscillation and rhythm generation in the CNS. J Neurosci Meth. 1989;28:93-9. (Pubitemid 19110215)
12. Iftinca MC, Zamponi GW. Regulation of neuronal T-type calcium channels. Trends Pharmacol Sci. 2009;30(1):32-40.
13. Carbone E, Lux HD. A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones. Nature. 1984;310:501-2. (Pubitemid 14052412)
14. Fox AP, Nowycky MC, Tsien RW. Single-channel recordings of three types of calcium channels in chick sensory neurones. J Physiol. 1987;394:173-200. (Pubitemid 18005129)
15. Shin HS, Cheong EJ, Choi S, Lee J, Na HS. T-type Ca2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol. 2008;8:33-41.
16. White G, Lovinger DM, Weight FF. Transient low-threshold Ca2+ current triggers burst firing through an after depolarizing potential in an adult mammalian neuron. Proc Natl Acad Sci USA. 1989;86:6802-6.
17. Todorovic SM, Jevtovic-Todorovic V. The role of T-type calcium channels in peripheral and central pain processing. CNS Neurol Disord Drug Targets. 2006;5(6):639-53. (Pubitemid 44890575)
18. Steriade M, McCormick DA, Sejnowski TJ. Thalamocortical oscillations in the sleeping and aroused brain. Science. 1993;262:679-85. (Pubitemid 23350685)
19. von Krosigk M, Bal T, McCormick DA. Cellular mechanisms of a synchronized oscillation in the thalamus. Science. 1993;261:361-4.
20. Hughes JR. Absence seizures: a review of recent reports with new concepts. Epilepsy Behav. 2009;15:404-12.
21. Lee J, Kim D, Shin HS. Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking alpha1G-subunit of T-type calcium channels. Proc Natl Acad Sci USA. 2004;101:18195-9. (Pubitemid 40054096)
22. Wilms H, Sievers J, Deuschl G. Animal models of tremor. Mov Disord. 1999;14:557-71. (Pubitemid 30011448)
23. Martin FC, Le Thu A, Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord. 2005;20:298-305. (Pubitemid 40613290)
24. Miwa H. Rodent models of tremor. Cerebellum. 2007;6:66-72. (Pubitemid 46410668)
25. Llinás R, Volkind RA. The olivo-cerebellar system: functional properties as revealed by harmaline-induced tremor. Exp Brain Res. 1973;18:69-87.
26. de Montigny C, Lamarre Y. Rhythmic activity induced by harmaline in the olivo-cerebello-bulbar system of the cat. Brain Res. 1973;53:81-95.
27. Bucher SF, Seelos KC, Dodel RC, Reiser M, Oertel WH. Activation mapping in essential tremor with functional magnetic resonance imaging. Ann Neurol. 1997;41:32-40. (Pubitemid 27057090)
28. Cavelier P, Lohof AM, Lonchamp E, Beekenkamp H, Mariani J, Bossu JL. Participation of low-threshold Ca2+ spike in the Purkinje cells complex spike. Neuroreport. 2008;19:299-303. (Pubitemid 351322966)
29. Sinton CM, Krosser BI, Walton KD, Llinás RR. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch. 1989;414:31-6. (Pubitemid 19140439)
30. Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci. 1999;19:1895-911. (Pubitemid 29133368)
31. Park YG, Park HY, Lee CJ, Choi S, Jo S, Choi H, et al. Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive. Proc Natl Acad Sci USA. 2010;107:10731-6.
32. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol. 1998;56:591-611. (Pubitemid 29012460)
33. Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A, et al. Dopamine agonists suppress cholinomimeticinduced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav Brain Res. 2005;156:173-9. (Pubitemid 39576057)
34. Kralic JE, Criswell HE, Osterman JL, O'Buckley TK, Wilkie ME, Matthews DB, et al. Genetic essential tremor in gammaaminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005;115:774-9. (Pubitemid 40322254)
35. Gomez-Mancilla B, Latulippe JF, Boucher R, Bédard PJ. Effect of ethosuximide on rest tremor in the MPTP monkey model. Mov Disord. 1992;7:137-41.
36. Handforth A, Homanics GE, Covey DF, Krishnan K, Lee JY, Sakimura K, et al. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology. 2010;59:380-7.
37. Miwa H, Koh J, Kajimoto Y, Kondo T. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacol Biochem Behav. 2011;97:656-9.
38. Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord. 2008;14:33-6.
39. Quesada A, Bui PH, Homanics GE, Hankinson O, Handforth A. Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. Eur J Pharmacol. 2011 Jan 21. [Epub ahead of print].
40. Gören MZ, Onat F. Ethosuximide: from bench to bedside. CNS Drug Rev. 2007;13:224-39. (Pubitemid 47052347)
41. Todorovic SM, Prakriya M, Nakashima YM, Nilsson KR, Han M, Zorumski CF, et al. Enantioselective blockade of T-type Ca2+ current in adult rat sensory neurons by a steroid that lacks gamma-aminobutyric acid-modulatory activity.Mol Pharmacol. 1998;54:918-27. (Pubitemid 28523184)
42. Park SJ, Park SJ, Lee MJ, Rhim H, Kim Y, Lee JH, et al. Synthesis and SAR studies of a novel series of T-type calcium channel blockers. Bioorg Med Chem. 2006;14:3502-11.
43. Lory P, Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets. 2007;11:717-22. (Pubitemid 46730085)
44. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, et al. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl) propyl]-N-methylamino)ethyl) -6-fluoro-1,2,3,4-tetrahydro-1- isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther. 2004;309:193-9. (Pubitemid 38393130)
45. Li M, Hansen JB, Huang L, Keyser BM, Taylor JT. Towards selective antagonists of T-type calcium channels: design, characterization and potential applications of NNC 55-0396. Cardiovasc Drug Rev. 2005;23:173-96. (Pubitemid 41278975)
46. Ishii M, Kobayashi S, Ohkura M, Yamamoto R, Shimizu S, Kiuchi Y. Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. J Pharmacol Sci. 2009;111:221-5.
47. Tang CM, Presser F, Morad M. Amiloride selectively blocks the low threshold (T) calcium channel. Science. 1988;240:213-5.
48. Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, et al. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calciumchannels. JMed Chem. 2008;51:6471-7.
49. Pourcher E, Gomez-Mancilla B, Bédard PJ. Ethosuximide and tremor in Parkinson's disease: a pilot study. Mov Disord. 1992;7:132-6.
50. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001;41:397-9. (Pubitemid 33733759)
51. Murata M, Hasegawa K. Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68:45-50. (Pubitemid 46058551)
52. Miwa H. Zonisamide for the treatment of Parkinson's disease. Expert Rev Neurother. 2007;7:1077-83. (Pubitemid 47451014)
53. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord. 2005;11:101-3. (Pubitemid 40279150)
54. Bermejo PE. Zonisamide in patients with essential tremor and Parkinson's disease. Mov Disord. 2007;22:2137-8.
55. Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol. 2007;30:345-9. (Pubitemid 350307313)
56. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord. 2007;22:279-82. (Pubitemid 46374780)
57. Song IU, Kim JS, Lee SB, Ryu SY, An JY, Kim HT, et al. Effects of zonisamide on isolated head tremor. Eur J Neurol. 2008;15:1212-5.
58. Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord. 2009;24:437-40.
59. Wills AJ, Jenkins IH, Thompson PD, Findley LJ, Brooks DJ. A positron emission tomography study of cerebral activation associated with essential and writing tremor. Arch Neurol. 1995;52:299-305.
60. Miwa H, Kubo T, Suzuki A, Kondo T. Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. Parkinsonism Relat Disord. 2009;15:30-5.
61. Sen S, Kawaguchi A, Truong Y, Lewis MM, Huang X. Dynamic changes in cerebello-thalamo-cortical motor circuitry during progression of Parkinson's disease. Neuroscience. 2010;166: 712-9.